Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis

Journal of Dermatology

Volumn 42, Issue 5, 2015, Pages 461-466

  Miura, Shunsuke ^a   Asano, Yoshihide ^a   Saigusa, Ryosuke ^a   Yamashita, Takashi ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Tamaki, Zenshiro ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Sato, Shinichi ^a   Kadono, Takafumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

omentin; pulmonary arterial hypertension; systemic sclerosis; vascular inflammation; vasodilation

Indexed keywords

ADIPOCYTOKINE; OMENTIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; VASCULITIS; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; COMPLICATION; DIFFUSE SCLERODERMA; LIMITED SCLERODERMA; MIDDLE AGED; TIME FACTOR; VASCULAR DISEASES;

AGED; BIOMARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; TIME FACTORS; VASCULAR DISEASES;

EID: 84928367977     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12824     Document Type: Article

References (41)

1. Abraham DJ, Krieg T, Distler J, Distler O,. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48 (Suppl 3): iii3-iii7.
2. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
3. Masui Y, Asano Y, Shibata S, et al,. Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 2012; 26: 354-360.
4. Masui Y, Asano Y, Takahashi T, et al,. Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. Mod Rheumatol 2013; 23: 323-329.
5. Masui Y, Asano Y, Shibata S, et al,. A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response. Rheumatology (Oxford) 2013; 52: 1239-1244.
6. Masui Y, Asano Y, Akamata K, et al,. Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis. Rheumatol Int 2014; 34: 1165-1170.
7. Toyama T, Asano Y, Takahashi T, et al,. Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2013; 27: 337-344.
8. Aozasa N, Asano Y, Akamata K, et al,. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2013; 27: 37-42.
9. Lakota K, Wei J, Carns M, et al,. Levels of adiponectin, a marker for PPAR-γ activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther 2012; 14: R102.
10. Fang F, Liu L, Yang Y, et al,. The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy. Arthritis Res Ther 2012; 14: R229.
11. Komiya T, Tanigawa Y, Hirohashi S,. Cloning of the novel gene intelectin, which is expressed in intestinal paneth cells in mice. Biochem Biophys Res Commun 1998; 251: 759-762.
12. Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C,. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005; 1732: 96-102.
13. Tan BK, Adya R, Randeva HS,. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20: 143-148.
14. Yang RZ, Lee MJ, Hu H, et al,. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-E1261.
15. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y,. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010; 393: 668-672.
16. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM,. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011; 19: 1552-1559.
17. Joannides R, Haefeli WE, Linder L, et al,. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-1319.
18. Prats-Puig A, Bassols J, Bargallõ E, et al,. Toward an early marker of metabolic dysfunction: omentin-1 in prepubertal children. Obesity (Silver Spring) 2011; 19: 1905-1907.
19. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H,. Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012; 686: 116-123.
20. Kazama K, Okada M, Yamawaki H,. A novel adipocytokine, omentin, inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell migration through antioxidative mechanism. Am J Physiol Heart Circ Physiol 2014; 306: H1714-H1719.
21. Amiya E, Takata M, Watanabe M, et al,. Presence of desaturated hemoglobin enhances the contribution of blood cells to flow-mediated dilation in subjects with systemic sclerosis. Int J Cardiol 2013; 168: 3125-3127.
22. Takahashi T, Asano Y, Amiya E, et al,. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. Mod Rheumatol 2012; 22: 598-601.
23. Takahashi T, Asano Y, Amiya E, et al,. Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis. Mod Rheumatol 2014; 24: 106-111.
24. LeRoy EC, Black C, Fleischmajer R, et al,. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
25. van den Hoogen F, Khanna D, Fransen J, et al,. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747.
26. Clements PJ, Lachenbruch PA, Seibold JR, et al,. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-1896.
27. Kazerooni EA, Martinez FJ, Flint A, et al,. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-983.
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
29. Alcelik A, Tosun M, Ozlu MF, et al,. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res 2012; 35: 511-516.
30. Hill MB, Phipps JL, Cartwright RJ, Milford WA, Greaves M, Hughes P,. Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 1996; 106: 491-497.
31. Rosenbaum J, Pottinger BE, Woo P, et al,. Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988; 72: 450-456.
32. Salojin KV, Le Tonquèze M, Saraux A, et al,. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997; 102: 178-185.
33. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G,. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000; 43: 2550-2562.
34. + T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 1998; 41: 327-334.
35. Kahaleh MB, Fan PS, Otsuka T,. γδ receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 1999; 91: 188-195.
36. Wolf SI, Howat S, Abraham DJ, Pearson JD, Lawson C,. Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vascul Pharmacol 2013; 59: 19-26.
37. Maruyama S, Shibata R, Kikuchi R, et al,. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012; 287: 408-417.
38. Luo Y, Wang Y, Wang Q, Xiao R, Lu Q,. Systemic sclerosis: genetics and epigenetics. J Autoimmun 2013; 41: 161-167.
39. Altorok N, Tsou PS, Coit P, Khanna D, Sawalha AH,. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2014-205303.
40. Wang Y, Fan PS, Kahaleh B,. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-2279.
41. Matouk CC, Marsden PA,. Epigenetic regulation of vascular endothelial gene expression. Circ Res 2008; 102: 873-887.